Stoke Therapeutics (STOK) Soars 8.98% on Positive Analyst Rating, Earnings Beat

Stoke Therapeutics (STOK) shares surged by 8.98% today, marking a significant rebound after hitting its lowest level since February 2024, with an intraday decline of 9.32%.

Analyst Sumant Kulkarni from CCORF has maintained a buy rating for Stoke Therapeutics, setting a target price of $20. This positive outlook from a reputable analyst likely contributed to the stock's recent surge, as investors responded favorably to the bullish sentiment.

In addition to the analyst rating, Stoke Therapeutics' Q4 2024 earnings report, released on March 24, 2025, also played a crucial role in the stock's performance. The company reported an EPS of -$0.18, which exceeded analysts' consensus estimates of -$0.56 by $0.38. This positive earnings surprise indicates that the company is performing better than expected, which has likely boosted investor confidence and driven the stock price higher.